Table 3.

List of lymphoid cancer stem cell genes that are affected via ruxolitinib usage and their clinical correlations.

Gene*	Physiological function**	Pathobiological alteration**	Possible disordered mechanism**	Related lymphoidneoplasms**
B-Cell related genes*CD19CD20CD23CD25CD22	B-lymphocyte development, growth, differentiation, determination of B-cell functions	Neoplastic aberrations resulting in numerous lymphoid malignant disorders	Pathological expression of the transcription factors, proliferation of malignant neoplastic B cells	T-cell lymphoma (21)B-cell lymphoma (22,23)Hodgkin lymphoma (24,25)Follicular lymphoma (26,27)
T-Cell related genes*CD5CD10LMP-1	T-cell proliferation, inactivation of critical peptide hormones important for lymphoid functions	Pathological alterations of transmembrane glycoproteins and lymphoid cell surface markers	Inhibition of cellular apoptosis	CLLSLLMCL (29)Nasal NK/T-cell lymphoma (30)
Lymphoid / lineage-related genes*CD45CD30CD15CD79CD138CD38CD43CD71	Regulation of signaling, lymphoid cellular processes including cell growth, differentiation, mitosis, oncogenic transformation, and immune activation	Pathological alterations of cellular proliferation, migration, and cell–matrix interactions	Neoplastic proliferation of B-lymphoid cells andplasma cells	DLBCL (31), NK/T-cell lymphoma (32), AITL (33), PTCL (NOS) (34),Hodgkin lymphoma (34),PTCL (35),extranodal NK/T-cell lymphoma (36),DLBCL (37), DLBCL (37), ATLL (20)

*Genes affected by ruxolitinib treatment. **Selected physiological actions, pathobiological alterations, possible mechanisms for the genesis of lymphoid neoplasms. CLL: Chronic lymphocytic leukemia, SLL: small lymphocytic lymphoma, MCL: mantle cell lymphoma, DLBCL: diffuse large B cell lymphoma, AITL: adult T-cell leukemia/lymphoma, PTCL: Peripheral T-cell lymphoma, ATLL: adult T-cell leukemia/lymphoma.